Early predictors of weight gain risk during treatment with olanzapine: Analysis of pooled data from 58 clinical trials

Psychopharmacology Bulletin

Volumn 42, Issue 4, 2009, Pages 23-39

  Lipkovich, Ilya ^a   Jacobson, Jennie G ^b   Caldwell, Cathy ^a   Hoffmann, Vicki Poole ^a   Kryzhanovskaya, Ludmila ^a   Beasley, Charles M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

Author keywords

Antipsychotic agents; Bipolar disorder; Body weight changes; Classification trees; Logistic regression; Predictive modeling; Schizophrenia

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR MANIA; BORDERLINE STATE; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; ROC CURVE; TIME FACTORS; WEIGHT GAIN;

EID: 79953021050     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gregg E, Cadwell B, Cheng Y, Cowie C, Williams D, Geiss L, Engelgau M, Vinicor F. Trends in the prevalence and ration of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004;27(12):2806-2812. (Pubitemid 39565041)
2. Goff D, Cather C, Evins A, Henderson D, Freudenreich O, Copeland P, Beirer M, Duckworth K, Sacks F. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.
3. Curkendall S, Mo J, Glasser D, Rose Stang M, Jones J. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004;65(5):715-720.
4. Kenna H, Jiang B, Rasgon N. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry. 2009;17(2):138-146.
5. Fiedorowicz J, Palagummi N, Forman-Hoffmann V, Miller del D, Haynes W. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorders. Ann Clin Psychiatry. 2008;20(3):131-137. (Pubitemid 352009283)
6. Allison D, Fontaine K, Heo M, Mentore J, Cappelleri J, Chandler L, Weiden P, Cheskin L. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-220. (Pubitemid 29193917)
7. Gasquet I, Haro J, Novick D, Edgell E, Kennedy L, Lepine J. SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol. 2005;20(4):199-205. (Pubitemid 40896374)
8. Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
9. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;28(1):27-31.
10. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697-701. (Pubitemid 29261358)
11. Daumit G, Goldberg R, Anthony C, Dickerson F, Brown C, Kreyenbuhl J, Wohlheiter K, Dixon L. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005;193(10):641-646. (Pubitemid 41475857)
12. Sokal J, Messias E, Dickerson F, Kreyenbuhl J, Brown C, Holdberg R, Dixon L. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192(6):421-427. (Pubitemid 38746100)
13. Thakore J. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl. 2004;47:S76-S79. (Pubitemid 38482548)
14. Lipkovich I, Jacobson J, Hardy T, Hoffmann V. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry. 2008;8:78-91.
15. Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston J, Ahl J, Hardy T. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3):316-320. (Pubitemid 43804625)
16. Kinon B, Basson B, Gilmore J, Tollefson G. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100. (Pubitemid 32199865)
17. Wirshing D, Wirshing W, Kysar L, Berisford M, Goldstein D, Pashdag J, Mintz J, Marder S. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60(6):358-363. (Pubitemid 29289721)
18. Breiman L, Friedman J, Olshen R, Stone C. Classification and Regression Trees. Monterey, CA: Wadsworth; 1984.
19. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd ed. New York, NY: Springer; 2009.
20. Kinon B, Kaiser C, Ahmed S, Rotelli M, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-258. (Pubitemid 40685790)